Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Completed 6Unknown 5Recruiting 2Active not recruiting 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 1780Triple Negative Breast Neoplasms 299Ovarian Neoplasms 136Lung Neoplasms 115Colorectal Neoplasms 115Neoplasms 106Prostatic Neoplasms 103Carcinoma, Non-Small-Cell Lung 101Neoplasm Metastasis 96Stomach Neoplasms 81Pancreatic Neoplasms 78Melanoma 74Endometrial Neoplasms 65Head and Neck Neoplasms 60Uterine Cervical Neoplasms 56Squamous Cell Carcinoma of Head and Neck 50Colonic Neoplasms 45Esophageal Neoplasms 42Sarcoma 41Carcinoma, Intraductal, Noninfiltrating 41Motor Activity 37HER2-positive Breast Cancer 34Urinary Bladder Neoplasms 33Liver Neoplasms 31Carcinoma, Renal Cell 30Brain Neoplasms 28Advanced Breast Cancer 25Lymphedema 24Kidney Neoplasms 24Carcinoma, Transitional Cell 23

Interventions

exemestane 1Fulvestrant 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Unilateral Breast Neoplasms × Breast × Clear all
NCT07187726 2026-05-19

PRE-ACT-01

UNICANCER

Phase NA Recruiting
724 enrolled
Breast

Unilateral Breast Neoplasms

NCT07062965 2026-05-06

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Pfizer

Phase 3 Recruiting
400 enrolled
Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡